Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency¹)

About this update from Insulet Corporation

[{"type":"text","content":"\nRaising Full Year Revenue and Gross Margin Guidance\n\n ACTON, Mass.--(BUSINESS WIRE)--\nInsulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2025.\n\n“Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet's new President and CEO, I see a path to scale the Company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our Podders,\" said Ashley McEvoy, President and CEO. \"I’d like to thank the team and Board of Directors for their incredible support. Insulet is just getting started on an exciting journey to revolutionize diabetes management globally. I am energized and honored to embark on that journey with all of you.”\n\nFirst Quarter Financial Highlights:\n\n\nRevenue of $569.0 million, up 28.8%, or 29.8% in constant currency, compared with $441.7 million in the prior year, exceeds the high end of the Company’s guidance range of 25% in constant currency\n\n\nTotal Omnipod revenue of $554.1 million, an increase of 28.0%, or 29.0% in constant currency\n\n\nU.S. Omnipod revenue of $401.7 million, an increase of 26.4%\n\n\nInternational Omnipod revenue of $152.4 million, an increase of 32.2%, or 36.1% in constant currency\n\n\n\n\nDrug Delivery revenue of $14.9 million\n\n\n\n\nGross margin of 71.9%, up 240 basis points, compared with 69.5% in the prior year\n\n\nOperating income of $88.8 million, or 15.6% of revenue, up 270 basis points, compared with $56.9 million, or 12.9% of revenue, in the prior year\n\n\nAdjusted operating income1 of $93.5 million, or 16.4% of revenue, up 350 basis points over prior year\n\n\nNet income of $35.4 million, or $0.50 per diluted share, compared with $51.5 million, or $0.73 per diluted share, in the prior year\n\n\nAdjusted net income1 of $73.7 million, or $1.02 per diluted share\n\n\nAdjusted EBITDA1 of $133.9 million, or 23.5% of revenue, up 330 basis points, compared with $89.2 million, or 20.2% of revenue, in the prior year\n\n\nOperating cash flow of $63.8 million, compared with $87...

More updates from Insulet Corporation